Allogeneic HCT Improves Survival Rates for TP53-Mutated MDS

A recent study suggests that patients with myelodysplastic syndrome (MDS) could potentially benefit from allogeneic hematopoietic cell transplantation (HCT) regardless of genetic mutation status.

Related Keywords

,Dana Farber Cancer Institute ,International Prognostic Scoring System ,Clinical Oncology ,Mds ,